C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...
Gilead Sciences
Gilead Terminates $2.3 B Collaboration With Kite Pharma Over Off‑the‑Shelf Cell Therapies
US-based Gilead Sciences’ (NASDAQ: GILD) subsidiary Kite Pharma has officially ended its $2.3 billion collaboration with Shoreline...
Gilead’s Seladelpar Approved for PBC Treatment in Beijing Pilot Zone
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that its oral primary biliary cholangitis (PBC) treatment,...
Kite Pharma Acquires Interius BioTherapeutics for $350 Million to Boost CAR Therapy Platform
On August 22, 2025, Kite Pharma, Inc., a subsidiary of Gilead Sciences (NASDAQ: GILD), announced...
FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies
The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...
Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD
US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...
Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP
US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...
Gilead Sciences to Acquire Hookipa’s HB-400 and HB-500 Vaccine Programs
US-based Gilead Sciences Inc. (Nasdaq: GILD) announced plans to acquire the HB-400 and HB-500 programs...
Gilead Sciences Announces $11 Billion Investment in US Expansion
US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...
Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...
Gilead Sciences’ Lenacapavir NDA for HIV Prevention Accepted by FDA for Priority Review
US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that the New Drug Application (NDA) for its...
Gilead Sciences’ Q4 2024 Financials Show 6% Revenue Growth, Driven by HIV and Oncology
Gilead Sciences Inc. (NASDAQ: GILD) reported a 6% year-on-year (YOY) increase in global revenues for...
MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis
The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...
Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead
Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...
Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC
US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with...
Gilead Sciences Reports 7% YOY Increase in Q3 2024 Product Sales, Driven by HIV Therapies
Gilead Sciences Inc., (NASDAQ: GILD), a major US-based pharmaceutical company, has released its financial results...
Shanghai Pharmaceutical Co., Ltd Secures Multiple Partnerships at CIIE
At the 7th China International Import Expo (CIIE), China-based Shanghai Pharmaceutical Co., Ltd (SPH, SHA:...
Gilead Sciences to Withdraw Accelerated Approval of Trodelvy in Urothelial Carcinoma
Gilead Sciences Inc., (NASDAQ: GILD), a leading US-based biopharmaceutical company, has announced its intention to...